These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18320029)

  • 1. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
    Waibler Z; Sender LY; Merten C; Hartig R; Kliche S; Gunzer M; Reichardt P; Kalinke U; Schraven B
    PLoS One; 2008 Mar; 3(3):e1708. PubMed ID: 18320029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
    Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
    MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.
    Singh M; Basu S; Camell C; Couturier J; Nudelman RJ; Medina MA; Rodgers JR; Lewis DE
    Eur J Immunol; 2008 Jun; 38(6):1522-32. PubMed ID: 18446791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells.
    He X; Smeets RL; van Rijssen E; Boots AM; Joosten I; Koenen HJ
    Sci Rep; 2017 Feb; 7():43003. PubMed ID: 28223693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.
    Gogishvili T; Langenhorst D; Lühder F; Elias F; Elflein K; Dennehy KM; Gold R; Hünig T
    PLoS One; 2009; 4(2):e4643. PubMed ID: 19247496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
    Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
    MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
    Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased interleukin-10 production by ASC-deficient CD4+ T cells impairs bystander T-cell proliferation.
    Narayan S; Kolly L; So A; Busso N
    Immunology; 2011 Sep; 134(1):33-40. PubMed ID: 21718313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD28 superagonists: what makes the difference in humans?
    Schraven B; Kalinke U
    Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.
    Elsayed A; Pellegrino C; Plüss L; Peissert F; Benz R; Ulrich F; Thorhallsdottir G; Plaza SD; Villa A; Mock J; Puca E; De Luca R; Manz MG; Halin C; Neri D
    MAbs; 2023; 15(1):2220839. PubMed ID: 37288872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.
    Tyrsin D; Chuvpilo S; Matskevich A; Nemenov D; Römer PS; Tabares P; Hünig T
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):45-8. PubMed ID: 27586803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased CD154 expression by neonatal CD4+ T cells is due to limitations in both proximal and distal events of T cell activation.
    Jullien P; Cron RQ; Dabbagh K; Cleary A; Chen L; Tran P; Stepick-Biek P; Lewis DB
    Int Immunol; 2003 Dec; 15(12):1461-72. PubMed ID: 14645155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.
    Beyersdorf N; Hanke T; Kerkau T; Hünig T
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv91-5. PubMed ID: 16239397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.
    Thaventhiran T; Wong W; Alghanem AF; Alhumeed N; Aljasir MA; Ramsey S; Sethu S; Yeang HXA; Chadwick AE; Cross M; Webb SD; Djouhri L; Ball C; Stebbings R; Sathish JG
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):60-69. PubMed ID: 31009338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional expression of human CD28 in murine T cell hybridomas.
    Couez D; Pagès F; Ragueneau M; Nunès J; Klasen S; Mawas C; Truneh A; Olive D
    Mol Immunol; 1994 Jan; 31(1):47-57. PubMed ID: 8302298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In CD28-costimulated human naïve CD4+ T cells, I-κB kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms.
    Lupino E; Buccinnà B; Ramondetti C; Lomartire A; De Marco G; Ricotti E; Tovo PA; Rinaudo MT; Piccinini M
    Immunology; 2010 Oct; 131(2):231-41. PubMed ID: 20465575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
    Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA
    J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.